News & Events
CPHI Milan 2026 | Lianhe Aigen: Two Engines, A New Chapter
Oct. 09, 2026
From a solid foundation to dual-engine momentum, Lianhe Aigen is opening a new chapter — with its well-established small molecule business as the ballast, its fast-growing oligonucleotide business as the growth engine, and proven capabilities in peptides and linkers, the company is building an integrated, multi-modality, one-stop CRDMO platfor
Oct. 08, 2026
To solidify the foundation of quality knowledge across the workforce and strengthen compliance awareness in all roles, Lianhe Aigen recently concluded its 3rd Quality Month series under the theme "Quality from Dedication, Expertise Driving Growth." Spanning multiple dimensions.
Sep. 30, 2026
Recently, the Drug Marketing Authorization Application for an innovative drug API, jointly developed by Lianhe Aigen and a key domestic pharmaceutical partner, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
Proud to Announce | Lianhe Aigen Awarded EcoVadis Platinum Medal, Ranking in the Top 1% Globally
Sep. 10, 2026
Lianhe Aigen has been awarded the Platinum Medal in the latest assessment by EcoVadis, a globally recognized sustainability rating agency, placing the company among the top 1% of all companies assessed worldwide.
Aug. 11, 2026
The newly unveiled synthesizer serves as the core hub of the strategic production line, undertaking key synthesis processes and quality control functions.
Consolidating the Foundation in Small Molecules, Setting Sail for the Future of Oligonucleotides
Jul. 20, 2026
As a trusted partner in the small-molecule CDMO space, we continue to strengthen our core business while proactively expanding into new frontiers—including oligonucleotide therapeutics—to build a more diversified service capability matrix.
How Can We Help You?
We provide customers with one-stop CRDMO services covering the entire lifecycle of drugs.